CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Synapse-tuned CARs enhance immune cell anti-tumor activity.
Synapse-tuned CARs enhance immune cell anti-tumor activity.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
嵌合抗原受体(CAR)技术已在血液系统恶性肿瘤的治疗中实现临床应用;然而,实体瘤对CAR治疗仍具有抵抗性。自然杀伤(NK)细胞由于其固有的抗肿瘤功能,可能为基于CAR的方法提供一类最优的免疫细胞。在本研究中,我们试图通过在CAR上添加一个细胞内支架蛋白结合位点来调节CAR免疫突触。我们采用了一个PDZ结合基序(PDZbm),该基序能够实现额外的支架交联,从而增强突触形成和NK CAR细胞极化。这种CAR设计的综合效应导致体外和体内效应细胞功能增强。此外,我们使用T细胞并观察到效应功能的类似整体增强。突触调节的CAR免疫细胞表现出突触强度放大、分泌细胞因子的数量和丰度增加、对肿瘤细胞的杀伤增强,以及在包括实体瘤在内的多种不同肿瘤模型中生存期延长。
Chimeric antigen receptor (CAR) technologies have been clinically implemented for the treatment of hematological malignancies; however, solid tumors remain resilient to CAR therapeutics. Natural killer (NK) cells may provide an optimal class of immune cells for CAR-based approaches due to their inherent anti-tumor functionality. In this study, we sought to tune CAR immune synapses by adding an intracellular scaffolding protein binding site to the CAR.
We employ a PDZ binding motif (PDZbm) that enables additional scaffolding crosslinks that enhance synapse formation and NK CAR cell polarization. Combined effects of this CAR design result in increased effector cell functionality in vitro and in vivo.
Additionally, we used T cells and observed similar global enhancements in effector function. Synapse-tuned CAR immune cells exhibit amplified synaptic strength, number and abundance of secreted cytokines, enhanced killing of tumor cells and prolonged survival in numerous different tumor models, including solid tumors.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。